Zydus Lifesciences completes phase IIa trial of Usnoflast in ALS patients - CNBC TV18
Zydus Lifesciences announced successful completion of Phase II(a) trial for Usnoflast, an NLRP3 inflammasome inhibitor, in ALS patients. The trial showed Usnoflast's safety, ability to reach therapeutic levels in blood and spinal fluid, and reduction of Neurofilament Light chain levels, suggesting potential benefits for neurodegenerative conditions. Improvements in ALS Functional Rating Scale and Slow Vital Capacity scores indicate Usnoflast may slow ALS progression.
Related Clinical Trials
Reference News
Zydus completes Phase II(a) study of NLRP3 inhibitor 'Usnoflast (ZYIL1)' in ALS patients, reporting therapeutic concentrations in CSF and reduced neurofilaments, with improvements in ALSFRS-R score and SVC. The study involved 24 ALS patients across 7 sites in India and will proceed to a larger Phase 2b trial. Usnoflast, an oral small molecule, has shown efficacy in pre-clinical models of neuroinflammation, Parkinson’s, IBD, and MS, and has received USFDA Orphan Drug Designation for CAPS treatment.
Zydus Lifesciences announced successful completion of Phase II(a) trial for Usnoflast, an NLRP3 inflammasome inhibitor, in ALS patients. The trial showed Usnoflast's safety, ability to reach therapeutic levels in blood and spinal fluid, and reduction of Neurofilament Light chain levels, suggesting potential benefits for neurodegenerative conditions. Improvements in ALS Functional Rating Scale and Slow Vital Capacity scores indicate Usnoflast may slow ALS progression.
Zydus Lifesciences completes Phase II(a) trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor for ALS, showing proof-of-concept, favorable safety, and trends towards reduction in neurodegeneration biomarkers.
Zydus completes Phase II(a) study of NLRP3 inhibitor Usnoflast (ZYIL1) in ALS patients, showing reduction in neurofilaments and improvements in ALSFRS-R score and SVC. Plans for Phase 2b trial.
Zydus Lifesciences Ltd. completed a Phase II(a) trial for Usnoflast (ZYIL1), an NLRP3 inflammasome inhibitor, in ALS patients, showing safety and potential benefits for neurodegenerative conditions. Usnoflast reduced Neurofilament Light chain levels and improved ALS Functional Rating Scale scores and Slow Vital Capacity, suggesting it may slow ALS progression. The trial marks a significant advancement in ALS therapy development.
Zydus Lifesciences completes Phase II(a) trial of Usnoflast, an oral NLRP3 inflammasome inhibitor for ALS, showing therapeutic concentrations in CSF and reduced neurofilaments, with encouraging improvements in ALSFRS-R score and SVC.